Interestingly, β2GPI is expressed in placental syncytiotrophoblasts and extravillous trophoblasts, and one of the key targets for antiphospholipid antibodies (aPL) that are associated with adverse pregnancy outcomes such as intrauterine growth restriction (IUGR), preeclampsia, and recurrent miscarriage [77]. This evidence concerns the gene FASLG and fetal growth restriction.